USFDA grants EIR to Neuland Labs for Pashamylaram facility

USFDA grants EIR to Neuland Labs for Pashamylaram facility

Avalokita Pandey
/ Categories: Trending

Pharmaceutical company, Neuland Laboratories Ltd, announced that it has received an establishment inspection report (EIR) for its manufacturing facility located at Pashamylaram in Hyderabad.

In a regulatory filing made on Thursday after the market hours, the company informed that it has received the EIR for its Unit 2 Pashamylaram manufacturing facility from United States Food & Drug Administration (USFDA).

Adding to this, the company said that the inspection was conducted from February 3 to 7, 2020 and has now been closed by USFDA.

Headquartered in Hyderabad (Telangana), Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the chemical needs of the pharmaceutical industry.

At the time of market closing on Friday, the stock of Neuland Laboratories Ltd was trading at Rs 427.95, up by 2.52 per cent against its previous close of Rs 417.45. Its 52-week high is recorded at Rs 734.20 while, its 52-week low is Rs 247.30 on BSE.

Previous Article Banks drag benchmarks down by 6 per cent for the week
Next Article Vista to invest in Reliance Jio
Rate this article:
3.6

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList